What is Axsome Therapeutics's net investment in lease?

Axsome Therapeutics (AXSM) reported net investment in lease of $20.01M in Q1 2026.

How has Axsome Therapeutics's net investment in lease changed year-over-year?

Axsome Therapeutics's net investment in lease decreased by 14.1% year-over-year, from $23.29M to $20.01M.

What is the long-term trend for Axsome Therapeutics's net investment in lease?

Over 5 years (2020 to 2025), Axsome Therapeutics's net investment in lease has grown at a 64.4% compound annual growth rate (CAGR), from $1.74M to $20.86M.

Axsome Therapeutics AXSM Net Investment in Lease

Net Investment in Lease at other companies

BridgeBio PharmaBBIO

——

Neurocrine BiosciencesNBIX

——

Jazz PharmaceuticalsJAZZ

——

Arrowhead ResearchARWR

——

BiogenBIIB

——

ALN

Alnylam PharmaceuticalsALNY

——

Other financials

Income statement

See full

Revenue$191.2M+57.4%

Gross profit$176.5M+58.0%

Operating income-$63.4M-11.2%

Net income-$64.5M-8.6%

EPS (diluted)-$1.26-3.3%

Balance sheet

See full

Cash & equivalents$305.1M+1.4%

Total debt$219.9M+4.1%

Total equity$54.6M+2.6%

Total assets$713.6M+19.6%

Cash flow

See full

Operating cash flow-$20.7M+52.3%

CapEx$121.0K-64.2%

Free cash flow-$20.8M+52.4%

Valuation

See full

Market cap$12.89B+52.0%

Enterprise value$12.81B+52.9%

P/S18.2×-1.4×

Profitability

See full

Gross margin92.6%+1.1pp

Operating margin-24.4%-9.3pp

Net margin-26.6%-9.8pp

FCF margin-10.2%-3.9pp

Returns & leverage

See full

Return on equity-349.4%+109pp

Debt / equity4×+0.1×

Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Axsome Therapeutics's net investment in lease?: Axsome Therapeutics (AXSM) reported net investment in lease of $20.01M in Q1 2026.
How has Axsome Therapeutics's net investment in lease changed year-over-year?: Axsome Therapeutics's net investment in lease decreased by 14.1% year-over-year, from $23.29M to $20.01M.
What is the long-term trend for Axsome Therapeutics's net investment in lease?: Over 5 years (2020 to 2025), Axsome Therapeutics's net investment in lease has grown at a 64.4% compound annual growth rate (CAGR), from $1.74M to $20.86M.